Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorTrustees of Dartmouth College
About this trial
The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is:
What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression?
Participants will
* Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview
Eligibility criteria
Qualifiers
Is 18 years or older.
Meet criteria for current CUD (CUDIT-R>=12) and MDD (PHQ-9>=10), and/or GAD (GAD-7>=10).
Have reliable access to the internet and a compatible device for Therabot-CALM.
Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study.
Disqualifiers
Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires.
Current psychosis (as determined by brief psychosis screen).
Current participation in another digital mental health intervention.
Trial design
Treatments tested in this trial
- Therabot-CALM
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Trustees of Dartmouth College
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov